Show Notes
(
00:32)
Can you tell our audience a little bit about yourself and your role here at Mayo Clinic?
(
01:29)
Can you tell our listeners a little bit about the disease state when we talk about autoimmune or paraneoplastic movement disorders?
(
02:37)
Are we seeing an increased prevalence of autoimmune movement disorders?
(
04:00)
Can you give our listeners an overview of what's going to be launched here in January?
(
06:56)
What other antibodies are particularly important in this phenotype?
(
10:01)
How does the kelch-like protein 11 phenotype manifest in this disorder?
(
10:49)
Are there any antibodies in the autoimmune neurology space that would not need to be evaluated for in patients that present with some sort of movement disorder?
(
11:18)
Which patients should have this testing and when should it be performed?
(
12:55)
When should Mayo Clinic Laboratories' stiff person evaluation and standalone glycine receptor tests be used, and in what order?
(
14:40)
Is the movement disorder evaluation the right first choice when the patient presentation is less typical and includes ataxia?
(
16:42)
Can physicians order the glycine receptor standalone test to fully evaluate the spectrum of antibodies?
(
18:39)
How does the evaluation impact patient care?
(
20:12)
Have these new antibodies been shown to be immunotherapy-responsive?
(
20:27)
Is there a key takeaway with the launch of these new antibodies in the movement disorder evaluation?